Media headlines about Deciphera Pharmaceuticals (NASDAQ:DCPH) have been trending somewhat positive recently, according to Accern. The research group identifies negative and positive press coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Deciphera Pharmaceuticals earned a coverage optimism score of 0.15 on Accern’s scale. Accern also gave news headlines about the company an impact score of 46.5188796354167 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.

Deciphera Pharmaceuticals (NASDAQ DCPH) opened at 19.19 on Wednesday. The company’s 50 day moving average price is $20.80 and its 200 day moving average price is $20.80. The stock’s market cap is $612.64 million. Deciphera Pharmaceuticals has a 12 month low of $16.11 and a 12 month high of $24.50.

A number of brokerages have commented on DCPH. Instinet began coverage on Deciphera Pharmaceuticals in a research note on Monday, October 23rd. They issued a “buy” rating and a $57.00 price objective for the company. Nomura initiated coverage on Deciphera Pharmaceuticals in a research note on Monday, October 23rd. They issued a “buy” rating and a $57.00 price objective for the company. JMP Securities initiated coverage on Deciphera Pharmaceuticals in a research report on Monday, October 23rd. They set an “outperform” rating and a $38.00 target price on the stock. Piper Jaffray Companies initiated coverage on Deciphera Pharmaceuticals in a research report on Monday, October 23rd. They set an “overweight” rating and a $35.00 target price on the stock. Finally, J P Morgan Chase & Co initiated coverage on Deciphera Pharmaceuticals in a research report on Monday, October 23rd. They set an “overweight” rating and a $30.00 target price on the stock. Five research analysts have rated the stock with a buy rating, The company presently has a consensus rating of “Buy” and an average price target of $43.40.

ILLEGAL ACTIVITY NOTICE: This article was first published by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are viewing this article on another domain, it was illegally stolen and reposted in violation of international copyright laws. The original version of this article can be accessed at https://theolympiareport.com/2017/11/01/deciphera-pharmaceuticals-dcph-earns-media-impact-score-of-0-15.html.

In related news, major shareholder New Leaf Venture Management Ii purchased 375,000 shares of the business’s stock in a transaction that occurred on Monday, October 2nd. The shares were bought at an average price of $17.00 per share, for a total transaction of $6,375,000.00. The acquisition was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Deciphera Pharmaceuticals Company Profile

Deciphera Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is developing drugs to improve the lives of cancer patients. Its drug candidate includes DCC-2618, DCC-3014 and Rebastinib. Its proprietary kinase switch control inhibitor platform, inhibit the activation of kinases.

Receive News & Ratings for Deciphera Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Deciphera Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.